Dataset Information

High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients.

ABSTRACT: Galectins are commonly overexpressed in cancer cells and their expression pattern is often associated with the aggressiveness and metastatic phenotype of the tumor. This study investigates the prognostic influence of the expression of galectin7 (Gal-7) and galectin8 (Gal-8) in tumor cell cytoplasm, nucleus and on surrounding immune cells. Primary breast cancer tissue of 235 patients was analyzed for the expression of Gal-7 and Gal-8 and correlated with clinical and pathological data and the outcome. To identify immune cell subpopulations, immunofluorescence double staining was performed. Significant correlations of Gal-7 expression in the cytoplasm with HER2-status, PR status, patient age and grading, and of Gal-8 expression in the cytoplasm with HER2-status and patient age and of both galectins between each other were found. A high Gal7 expression in the cytoplasm was a significant independent prognosticator for an impaired progression free survival (PFS) (p = 0.017) and distant disease-free survival (DDFS) (p = 0.030). Gal-7 was also expressed by tumor-infiltrating macrophages. High Gal-8 expression in the cytoplasm was associated with a significantly improved overall survival (OS) (p = 0.032). Clinical outcome in patients showing both high Gal-7 and with low Gal-8 expression was very poor. Further understanding of the role of galectins in the regulation and interaction of tumor cells and macrophages is essential for finding new therapeutic targets.

SUBMITTER: Trebo A

PROVIDER: S-EPMC7226378 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients.

Trebo Anna A Ditsch Nina N Kuhn Christina C Heidegger Helene Hildegard HH Zeder-Goess Christine C Kolben Thomas T Czogalla Bastian B Schmoeckel Elisa E Mahner Sven S Jeschke Udo U Hester Anna A

Cancers 20200412 4

Galectins are commonly overexpressed in cancer cells and their expression pattern is often associated with the aggressiveness and metastatic phenotype of the tumor. This study investigates the prognostic influence of the expression of galectin7 (Gal-7) and galectin8 (Gal-8) in tumor cell cytoplasm, nucleus and on surrounding immune cells. Primary breast cancer tissue of 235 patients was analyzed for the expression of Gal-7 and Gal-8 and correlated with clinical and pathological data and the outc ...[more]

PMID: 32290551

Similar Datasets

Project description:Deciphering how plants interact with each other across environmental gradients is important to understand plant community assembly, as well as potential future plant responses to environmental change. Plant-plant interactions are expected to shift from predominantly negative (i.e. competition) to predominantly positive (i.e. facilitation) along gradients of environmental severity. However, most experiments examine the net effects of interactions by growing plants in either the presence or absence of neighbours, thereby neglecting the interplay of both negative and positive effects acting simultaneously within communities. To partially unravel these effects, we tested how the seedling establishment of 10 mountain grassland plants varied in the presence versus absence of plant communities at two sites along an elevation gradient. We created a third experimental treatment (using plastic plant mats to mimic surrounding vegetation) that retained the main hypothesised benefits of plant neighbours (microsite amelioration), while reducing a key negative effect (competition for soil resources). In contrast to our expectations, we found evidence for net positive effects of vegetation at the low elevation site, and net negative effects at the high elevation site. Interestingly, the negative effects of plant neighbours at high elevation were driven by high establishment rates of low elevation grasses in bare soil plots. At both sites, establishment rates were highest in artificial vegetation (after excluding two low elevation grasses at the high elevation site), indicating that positive effects of above-ground vegetation are partially offset by their negative effects. Our results demonstrate that both competition and facilitation act jointly to affect community structure across environmental gradients, while emphasising that competition can be strong also at higher elevations in temperate mountain regions. Consequently, plant-plant interactions are likely to influence the establishment of new, and persistence of resident, species in mountain plant communities as environments change.Supplementary informationThe online version contains supplementary material available at 10.1007/s00035-023-00302-8.

Project description:BackgroundWe evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism that could eventually obtain long term benefit in these patients.MethodsHER2-negative ABC patients received 21-day cycles of pembrolizumab 200 mg (day 1) and gemcitabine (days 1 and 8). A run-in-phase (6 + 6 design) was planned with two dose levels (DL) of gemcitabine (1,250 mg/m2 [DL0]; 1,000 mg/m2 [DL1]) to determine the recommended phase II dose (RP2D). The primary objective was objective response rate (ORR). Tumor infiltrating lymphocytes (TILs) density and PD-L1 expression in tumors and myeloid-derived suppressor cells (MDSCs) levels in peripheral blood were analyzed.ResultsFourteen patients were treated with DL0, resulting in RP2D. Thirty-six patients were evaluated during the first stage of Simon's design. Recruitment was stopped as statistical assumptions were not met. The median age was 52; 21 (58%) patients had triple-negative disease, 28 (78%) visceral involvement, and 27 (75%) ≥ 2 metastatic locations. Progression disease was observed in 29 patients. ORR was 15% (95% CI, 5-32). Eight patients were treated ≥ 6 months before progression. Fourteen patients reported grade ≥ 3 treatment-related adverse events. Due to the small sample size, we did not find any clear association between immune tumor biomarkers and treatment efficacy that could identify a subgroup with higher probability of response or better survival. However, patients that experienced a clinical benefit showed decreased MDSCs levels in peripheral blood along the treatment.ConclusionPembrolizumab 200 mg and gemcitabine 1,250 mg/m2 were considered as RP2D. The objective of ORR was not met; however, 22% patients were on treatment for ≥ 6 months. ABC patients that could benefit of chemoimmunotherapy strategies must be carefully selected by robust and validated biomarkers. In our heavily pretreated population, TILs, PD-L1 expression and MDSCs levels could not identify a subgroup of patients for whom the combination of gemcitabine and pembrolizumab would induce long term benefit.Trial registrationClinicalTrials.gov and EudraCT (NCT03025880 and 2016-001,779-54, respectively). Registration dates: 20/01/2017 and 18/11/2016, respectively.

Dataset Information

High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients.

Publications

High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets